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Abstract
Neisseria meningitidis, the cause of meningococcal disease, has been the subject of sophisticated molecular epidemiological investigation as a
consequence of the signiﬁcant public health threat posed by this organism. The use of multilocus sequence typing and whole genome
sequencing classiﬁes the organism into clonal complexes. Extensive phenotypic, genotypic and epidemiological information is available on the
PubMLST website. The human nasopharynx is the sole ecological niche of this species, and carrier isolates show extensive genetic diversity
as compared with hyperinvasive lineages. Horizontal gene exchange and recombinant events within the meningococcal genome during
residence in the human nasopharynx result in antigenic diversity even within clonal complexes, so that individual clones may express, for
example, more than one capsular polysaccharide (serogroup). Successful clones are capable of wide global dissemination, and may be
associated with explosive epidemics of invasive disease.
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Neisseria meningitidis causes meningococcal disease, which is
typically a rapidly evolving syndrome resulting from bactera-
emia, with or without target organ involvement (e.g. menin-
gitis). The disease has devastating consequences if not treated
promptly. The incidence of disease varies from region to
region, from <2 cases/100 000 population per annum (e.g.
France, Germany, Italy, Sweden, Poland, the USA, and China)
to >10/100 000 per annum in some countries, particularly in
Africa (e.g, Burkina Faso, Niger, Guinea Bissau, and Angola)
[1]. Characteristically, there is background endemnicity and
seasonality in most parts of the world, with occasionally
explosive epidemics of disease.
Humans are the only animal hosts of N. meningitidis, and the
nasopharynx provides a stable ecological niche. Colonization
of the nasopharynx is quite common, with cross-sectional
carriage rates ranging from 10% to 35%. Whereas disease is
most common in infants, carriage is most frequent in young
adults (with some university students in the UK having carriage
rates as high as 55%) [2], but is paradoxically rare in infants [3].
Invasive disease is rare, and occurs after translocation of
carried organisms into the bloodstream, a process that has an
undetermined mechanism.
Phenotypic typing of meningococci utilizes capsular poly-
saccharide, outer membrane protein and lipopolysaccharide
immunotypes. Most clinicians are familiar with the serogroups
based on capsular polysaccharides, because these form the
basis of current polysaccharide vaccines directed against
serogroups A, W, C, and Y. New vaccines are capable of
generating antibody responses against subcapsular antigens,
and therefore provide broader protection, including against
serogroup B meningococci [4], which express a non-immuno-
genic polysialic acid capsule.
Across Europe, the average mortality rate of meningococcal
disease is 8% [5]; characteristically, patients who develop
meningitis as part of their clinical picture have a lower
mortality rate, and those who present predominantly with
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severe sepsis have a higher rate. Occasionally, the peaks of
epidemiological activity may be associated with unusually high
fatality rates, well-documented examples being disease caused
by serogroup C meningococci, which occurred in the UK
during the mid-1990s [6], and disease in southern Africa, which
was caused by serogroup W approximately 10 years ago [7].
Basis of Molecular Typing
Modern typing of meningococcal isolates is conducted with
multilocus sequence typing (MLST), which compares 450–
500-bp nucleotide sequences of internal fragments of seven
‘housekeeping’ genes: abcZ, adk, aroE, fumC, gdh, pdhC, and
pgm. Distinct alleles at each of the loci are assigned numbers to
produce seven-digit allelic proﬁles. The sequence types (STs)
identiﬁed in this way can be grouped into closely related clonal
groups or clonal complexes (CCs) [8]. This system of
epidemiological typing was adopted, developed and propagated
by the European Society for Meningococci with the support of
the EU, and rapidly gained credence intenationally. Further
resolution has been gained by whole genome sequencing, and,
as of April 2014, there are >10 000 STs listed on the Neisseria
MLST website (http://pubmlst.org/neisseria/), which was
developed by Keith Jolley and is sited at the University of
Oxford [9]. Some data sourced from this website are shown in
Tables 1 and 2, although the information shown in these tables
represents only a tiny fraction of the available genotypic,
phenotypic and epidemiological knowledge available to users.
Of 46 CCs identiﬁed in PubMLST (which comprises submitted
data only, and so is not epidemiologically comprehensive) 41
have been associated with at least some form of invasive
disease and ﬁve have been isolated only from throat swabs of
asymptomatic carriers. Detection of newly emergent variants
with such molecular typing systems is highly relevant to public
health, because it helps track the emergence of new CCs,
which is particularly important if the new variants have
different epidemiological or disease characteristics (such as a
higher case-fatality rate, or higher transmissability) or contain
antigens that afford escape from current vaccine strategies.
Clones and Phenotypes
N. meningitidis is a panmitic organism, and frequent recombi-
nation events are observed through the analysis of sequence
variation in multiple genes, including the housekeeping enzyme
genes utilized in MLST. There is a mosaic genomic structure
TABLE 1. Serogroups of representative clonal complexes
Country
ST11 complex/
ET37 complex ST213 ST22
ST23 cluster/




subgroup 3 ST 4821
A 0 0 0 0 0 0 0.1 97.3 1.9
B 7.9 72.9 6.8 2.3 76.5 84.7 76.3 0.3 50.6
C 61.6 2.1 1.3 0.8 4.2 3.0 4.3 0.8 28.1
W 19.6 0.2 54.3 2.1 0.2 0.1 0.1 0 3.1
X 0 0 0.3 0 0 0.1 0.2 0.1 1.3
Y 0.6 0 7.6 69.9 0.1 0.2 0.3 0.1 0
NG 0.6 6.4 17.2 9.0 3.4 2.6 5.7 0.7 0.6
Others 9.7 18.4 12.5 17.9 15.6 9.3 13.0 0.5 14.4
ST, sequence type.
Numbers are the percentages of isolates of Neisseria meningitidis from representative clonal complexes that express the serogroup shown. Data are from the Neisseria MLST
website (http://pubmlst.org/neisseria/).
TABLE 2. Some selected clonal complexes by country
Country
ST11 complex/
ET37 complex ST213 ST22
ST23 cluster/




subgroup 3 ST 4821
Australia 5.8 6.9 0.6 1.2 9.2 9.2 32.9 0 0
Burkina Faso 6.3 0 0 6.5 0 0 1.3 54.5 0
Canada 20.1 1.7 4.8 4.1 4.5 6.2 17.0 0.2 0
China 1.3 0 0 0 0.1 2.6 5.1 5.2 17.0
France 16.3 0 1.5 1.3 2.9 8.7 15.0 0.5 0.1
Germany 5.6 0.5 2.3 4.6 2.2 9.5 17.4 0 0
Spain 17.8 2.4 2.2 0.7 4.7 14.5 9.0 0.1 0
UK 7.4 5.3 4.3 4.7 10.6 4.0 17.1 0.1 0
USA 13.2 0.5 2.8 8.1 2.0 3.8 9.8 0.1 0.1
ST, sequence type.
Numbers are the percentages of isolates of Neisseria meningitidis that are members of the clonal complex shown in each represented country (e.g. 17% of N. meningitidis isolates
collected in this resource from China are ST4821). Data are derived from the Neisseria MLST website (http://pubmlst.org/neisseria/).
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resulting from incorporation of foreign DNA at multiple loci
[10] together with spontaneous chromosomal mutations, so
that meningococci evolve over time from their parental
strains. One consequence of this is that cardinal meningococ-
cal antigens, such as capsular polysaccharide, but also outer
membrane proteins, are not always identical within collections
of individual CCs [11]. For example, one of the commonest
disease-associated clonal CCs, ST11/ET37, which has been
responsible for lethal meningococcal disease emerging as
epidemics in several global regions, mostly comprises bacteria
that express the a2,9-linked polysialic acid of serogroup C.
However, approximately 20% of the ST11/ET37 isolates listed
in the pubMLST resource express Neu5Ac-containing disac-
charide heteropolymers of serogroup W (Table 1). The
overwhelming majority of CC269 and CC32 isolates express
the a2,8-linked polysialic acid of serogroup B (Table 1), but,
among CC4821 isolates, 50% are serogroup B and at least
one-quarter are serogroup C. Capsular polysaccharide is
transcribed from the cps genome region, which can be
occupied by one of several possible gene clusters [12]. For
example, if it contains csb, then the organism can be
serogroup B; likewise, if it contains csc, csw, or csy, it may be
serogrouped as C, W, or Y respectively [13]. If it contains a
115-bp intergenic region, the capsule null locus (cnl), then it
will lack the genes necessary for capsular synthesis and
transport, and be phenotypically non-groupable [14]. Different
serogroups and cnl are generally associated with particular
CCs [15], but the cps locus can be subject to horizontal genetic
exchange among meningococci, as a manifestation of random
genetic variation [16,17]. Thus, two strains that share a
common CC can belong to entirely different serogroups.
However, it is not only capsular polysaccharide that is subject
to genetic variation within CCs. Protein antigens such as PorA,
PorB and fetA are easily identiﬁed phenotypically, and are
strongly immunogenic; indeed, PorA and PorB are each utilized
in serotyping and subserotyping, and all three are potential
vaccine candidates. They generally associate with CCs, but are
subject to considerable variation within complexes, probably
because of immune selection [18]. Factor H-binding protein is
included in the new subcapsular (protein) vaccines currently
being deployed and developed to protect the population from
serogroup B disease. These also show variation [19] and
striking heterogeneity even within CCs.
Carriage and Disease
Within geographical regions, disease isolates (e.g. from blood
and cerebrospinal ﬂuid) of N. meningitidis tend to be from a
limited range of CCs. A number of CCs have an increased
likelihood of being associated with disease (e.g. ST11/ET37),
and these are referred to as hypervirulent lineages. In
contrast, isolates from carriers are, genetically, relatively
heterogeneous. This is unsurprising, given that the nasophar-
ynx is the sole ecological niche for adaptation and survival of
N. meningitidis, and invasion confers no advantage in evolu-
tionary terms. Relatively few ‘carrier isolates’ belong to
hyperinvasive clones [3]. Using MLST of isolates from patients
and carriers from the Czech Republic, Greece, and Norway,
Yazdankhah et al. [11] showed that a large proportion of
carrier isolates were not from CCs that had previously been
associated with disease. They measured the ratio of patient to
carrier isolates of the various CCs in the collection, and found
that CC11, CC32 and CC269 were strongly associated with
disease, whereas CC23 and CC35 were positively associated
with carriage. From this, it is clear that CCs differ in their
pathogenic potential. Apparently, this is true not only for
disease susceptibility, but also for disease severity. Using a
large European database, Trotter et al. [5] measured the
relative case-fatality rates associated with infection with
invasive isolates. With the ST41/44 complex (the most
common complex in the dataset) as a baseline, the odds of
death were signiﬁcantly higher for the ST11/ET37 complex
(OR 2.19) and ST32/ET5 complex (OR 1.59). This difference
is not attributable to expression of the different capsular
polysaccharides, as many carrier isolates express capsule.
Genomic difference analysis has not identiﬁed a core pathog-
enome associated with disease [20], and the mechanism that
underlies the hyperinvasiveness of some lineages remains
obscure.
Geographical Distribution and Longevity of
Clones
Watkins and Maiden [21] interrogated the PubMLST records,
and found that a number of CCs have persisted for at least
several decades, including strains of the disease-associated
serogroup B, which are antigenically highly diverse. This
longevity has been reﬂected in the worldwide spread of some
hyperinvasive CCs. Good examples of successful CCs include
CC11 (which expresses mostly serogroups B and C), which
spread between Europe and North and South America in the
period 1961–2009, and CC41/44 (mostly serogroup B or
non-groupable), which has been circulating in 11 countries
worldwide for >26 years. Representative strains were isolated
frequently in the UK in 1995, followed by The Netherlands,
Germany, and New Zealand. Strains belonging to the highly
successful ST32 (ET5) complex were ﬁrst described in the
1970s (expressing mostly serogroup B), including epidemics in
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Norway from 1974 onwards, which prompted the develop-
ment of the MenBVac OMV vaccine. Related strains of CC32
then emerged in the UK in 1985, and have been recorded in
the USA and France. Table 2 shows examples of countries
from which large collections have been submitted to the
PubMLST database, and some of the more frequent CCs in
speciﬁed countries. European countries have relatively similar
CC distributions, whereas North America has some subtle
differences, such as relatively high rates of ST11/ET37 CC.
Sub-Saharan Africa is strikingly different (represented in
Table 2 by Burkina Faso). Here, serogroup A organisms have
dominated the epidemiology for at least 20 years, predomi-
nantly members of CC5. A change occurred in the mid-1990s,
when CC5 was gradually replaced by CC7 throughout Africa.
Then, in 2001, serogroup W strains belonging to CC11 spread
from the Middle East into Africa [22].
Recent Epidemics
This emergence of CC11 strains in Africa was a classic
example of geographical expansion of a successful clone. The
epidemic was identiﬁed in 2001 as being associated with
the Hajj pilgrimage, with disease emerging throughout Europe.
The clone spread to sub-Saharan Africa and then South Africa,
with a rapidly increasing disease incidence in 2006 and a
disease severity that was much greater than that associated
with endemic South African strains prevalent at the time [7],
consistent with the case-fatality rate of CC11 strains. Recently,
in North America, there have been disease outbreaks caused
by CC269, which has hitherto been prominent in Europe
(expressing serogroup B) but extremely rare in the USA. One
prolonged outbreak was well documented in university
students in Ohio [23] and among young adults and adolescents
in Quebec, Canada [24], with isolates showing very little
genetic diversity. Very recently, emerging disease at Princeton
University caused by serogroup B organisms prompted the
ﬁrst deployment of the ﬁrst vaccine (4CMenB) capable of
eliciting antibody against serogroup B strains. At the time of
writing, the CC of the disease strain had not been published.
Conclusions
Probably because of the severity of meningococcal disease,
genomic technologies have been extensively used to enable
detailed molecular epidemiological investigation of N. menin-
gitidis. This has revealed a limited range of hypervirulent
lineages, which tend to partition into geographical regions.
Because of the ease of horizontal gene transfer in this
organism, individual clones are capable of expressing widely
different antigens (e.g. capsular polysaccharide). Emerging
clones can cause explosive epidemics, and spread rapidly
within countries and internationally.
Transparency Declaration
RCR received a speaker honorarium and travel assistance from
Novartis Vaccines and Diagnostics within the last 3 years.
References
1. Jafri RZ, Ali A, Messonnier NE et al. Global epidemiology of invasive
meningococcal disease. Popul Health Metr 2013; 11: 17–26.
2. Ala’aldeen DA, Oldﬁeld NJ, Bidmos FA et al. Carriage of meningococci
by university students, United Kingdom. Emerg Infect Dis 2011; 17:
1762–1763.
3. Caugant DA, Tzanakaki G, Kriz P. Lessons from meningococcal
carriage studies. FEMS Microbiol Rev 2007; 31: 52–63.
4. Giuliani MM, Adu-Bobie J, Comanducci M et al. A universal vaccine for
serogroup B meningococcus. Proc Natl Acad Sci USA 2006; 103:
10834–10839.
5. Trotter CL, Chandra M, Cano R et al. A surveillance network for
meningococcal disease in Europe. FEMS Microbiol Rev 2007; 31: 27–36.
6. Read RC, Cannings C, Naylor SC et al. Variation within genes
encoding interleukin-1 and the interleukin-1 receptor antagonist
inﬂuence the severity of meningococcal disease. Ann Intern Med 2003;
138: 534–541.
7. von Gottberg A, du Plessis M, Cohen C et al. Emergence of endemic
serogroup W135 meningococcal disease associated with a high
mortality rate in South Africa. Clin Infect Dis 2008; 46: 377–386.
8. Maiden MC, Bygraves JA, Feil E et al. Multilocus sequence typing: a
portable approach to the identiﬁcation of clones within populations of
pathogenic microorganisms. Proc Natl Acad Sci USA 1998; 95: 3140–
3145.
9. Jolley KA, Maiden MC. BIGSdb: Scalable analysis of bacterial genome
variation at the population level. BMC Bioinformatics 2010; 11: 595–606.
10. Zhou J, Spratt BG. Sequence diversity within the argF, fbp and recA
genes of natural isolates of Neisseria meningitidis: interspecies recom-
bination within the argF gene. Mol Microbiol 1992; 6: 2135–2146.
11. Yazdankhah SP, Kriz P, Tzanakaki G et al. Distribution of serogroups
and genotypes among disease-associated and carried isolates of
Neisseria meningitidis from the Czech Republic, Greece, and Norway.
J Clin Microbiol 2004; 42: 5146–5153.
12. Frosch M, Weisgerber C, Meyer TF. Molecular characterization and
expression in Escherichia coli of the gene complex encoding the
polysaccharide capsule of Neisseria meningitidis group B. Proc Natl Acad
Sci USA 1989; 86: 1669–1673.
13. Harrison OB, Claus H, Jiang Y et al. Description and nomenclature of
Neisseria meningitidis capsule locus. Emerg Infect Dis 2013; 19: 566–573.
14. Claus H, Maiden MC, Maag R, Frosch M, Vogel U. Many carried
meningococci lack the genes required for capsule synthesis and
transport. Microbiology 2002; 148: 1813–1819.
15. Caugant DA, Maiden MC. Meningococcal carriage and disease—
population biology and evolution. Vaccine 2009; 27(suppl 2): B64–B70.
16. Holmes EC, Urwin R, Maiden MC. The inﬂuence of recombination on
the population structure and evolution of the human pathogen
Neisseria meningitidis. Mol Biol Evol 1999; 16: 741–749.
ª2014 The Author
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, 391–395
394 Clinical Microbiology and Infection, Volume 20 Number 5, May 2014 CMI
17. Jolley KA, Kalmusova J, Feil EJ et al. Carried meningococci in the Czech
Republic: a diverse recombining population. J Clin Microbiol 2000; 38:
4492–4498.
18. Urwin R, Russell JE, Thompson EA, Holmes EC, Feavers IM, Maiden
MC. Distribution of surface protein variants among hyperinvasive
meningococci: implications for vaccine design. Infect Immun 2004; 72:
5955–5962.
19. Ibarz-Pavon AB, Maclennan J, Andrews NJ et al. Changes in serogroup and
genotype prevalence among carried meningococci in the United Kingdom
during vaccine implementation. J Infect Dis 2011; 204 : 1046–1053.
20. Schoen C, Blom J, Claus H et al. Whole-genome comparison of
disease and carriage strains provides insights into virulence evolution
in Neisseria meningitidis. Proc Natl Acad Sci USA 2008; 105: 3473–
3478.
21. Watkins ER, Maiden MC. Persistence of hyperinvasive meningococcal
strain types during global spread as recorded in the PubMLST database.
PLoS ONE 2012; 7: e45349.
22. Caugant DA, Nicolas P. Molecular surveillance of meningococcal
meningitis in Africa. Vaccine 2007; 3(25 suppl 1): A8–A11.
23. Mandal S, Wu HM, MacNeil JR et al. Prolonged university outbreak of
meningococcal disease associated with a serogroup B strain rarely seen
in the United States. Clin Infect Dis. 2013; 57: 344–348.
24. Zhou JS, Lefebvre B, Deng S et al. Invasive serogroup B Neisseria
meningitidis in Quebec, Canada, 2003 to 2010: persistence of the
ST-269 clone since it ﬁrst emerged in 2003. J Clin Microbiol. 2012; 50:
1545–1551.
ª2014 The Author
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, 391–395
CMI Read N. meningitidis; clones, carriage, and disease 395
